美罗华联合CHOP方案治疗B细胞性非霍奇金淋巴瘤疗效观察

目的评价美罗华(Rituximab)联合CHO(PR-CHOP)治疗CD20阳性B细胞性非霍奇金淋巴瘤(NHL)的临床疗效及不良反应。方法回顾性分析治疗的39例初治CD20阳性B细胞性非霍奇金淋巴瘤(NHL)患者。其中R-CHOP组19例,采用R-CHOP方案化疗;CHOP组20例,采用CHOP方案化疗。6个疗程后比较两组的临床疗效及不良反应。结果 RCHOP组完全缓解率为73.7%(17/19),总有效率为89.5%(14/19);CHOP组分别为45.0%(9/20),75.0%(15/20),两组完全缓解率差异有统计学意义(P<0.05)。两组不良反应差异无统计学意义(P>0.05)。结论 R-CHOP方案治疗CD20阳性B细胞性非霍奇金淋巴瘤疗效更好,且未增加不良反应。

Objective To evaluate the efficacy and side-effects of CHOP combined with rituximab（R-CHOP） in treating CD 20 positive B-cell non-hodgkin lymphoma （NHL）.Methods We retrospectively analyzed 39 newly diagnosed patients with B-cell NHL who treated in our hospital.19 cases in R-CHOP group were treated with R-CHOP while 20 cases in CHOP group were treated with CHOP.The efficacy and side-effects of these two groups were evaluated after 6 courses of treatment.Results The complete remission（CR） rate and total effective rate in R-CHOP group was 73.7%（14/19） and 89.5%（17/19）,while the complete remission（CR） rate and total effective rate in CHOP group was 45.0%（9/20） and 75.0%（15/20）.The complete remission（CR） rate between the two groups had statistical significance（P0.05）,while the side-effects differences between the two groups had no statistical significance（P0.05）.Conclusion Treating CD 20 positive B-cell NHL with R-CHOP is more effective,while there are no additional side-effects.